Angiographic changes from baseline to follow up in the non-dilated lesions of the intention to treat (n = 3373) and the per protocol population (n = 3100)
| Intention to treat | Per protocol | |||
|---|---|---|---|---|
| Nisoldipine (n=1582) | Placebo (n=1791) | Nisoldipine (n=1483) | Placebo (n=1617) | |
| Values are mean (SD). | ||||
| Differences between treatment groups are non-significant. | ||||
| FU, follow up; MLD, minimum luminal diameter. | ||||
| MLD (mm) | ||||
| Baseline | 1.94 (0.68) | 1.96 (0.65) | 1.94 (0.67) | 1.97 (0.64) |
| FU | 1.78 (0.68) | 1.80 (0.66) | 1.77 (0.67) | 1.80 (0.66) |
| FU−baseline | −0.15 (0.43) | −0.16 (0.41) | −0.16 (0.43) | −0.17 (0.41) |
| Reference (mm) | ||||
| Baseline | 3.03 (0.80) | 3.04 (0.77) | 3.02 (0.80) | 3.06 (0.77) |
| FU | 2.88 (0.76) | 2.89 (0.75) | 2.87 (0.75) | 2.90 (0.74) |
| FU−baseline | −0.15 (0.47) | −0.15 (0.48) | −0.15 (0.46) | −0.16 (0.48) |
| Diameter stenosis (%) | ||||
| Baseline | 36.6 (11.6) | 36.2 (11.2) | 36.4 (11.5) | 36.1 (11.1) |
| FU | 38.5 (14.3) | 38.3 (14.4) | 38.7 (14.2) | 38.3 (14.3) |
| FU/baseline | 1.10 (0.44) | 1.10 (0.42) | 1.10 (0.40) | 1.10 (0.40) |